2.98
price down icon10.51%   -0.35
after-market After Hours: 2.98
loading
Mainz Biomed N V stock is traded at $2.98, with a volume of 90,730. It is down -10.51% in the last 24 hours and down -39.80% over the past month. Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
See More
Previous Close:
$3.33
Open:
$3.13
24h Volume:
90,730
Relative Volume:
0.44
Market Cap:
$6.62M
Revenue:
$895.50K
Net Income/Loss:
$-26.30M
P/E Ratio:
-1.8171
EPS:
-1.64
Net Cash Flow:
$-23.84M
1W Performance:
-16.76%
1M Performance:
-39.80%
6M Performance:
-69.20%
1Y Performance:
-93.10%
1-Day Range:
Value
$2.65
$3.13
1-Week Range:
Value
$2.65
$3.64
52-Week Range:
Value
$2.65
$45.20

Mainz Biomed N V Stock (MYNZ) Company Profile

Name
Name
Mainz Biomed N V
Name
Phone
-
Name
Address
-
Name
Employee
71
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
MYNZ's Discussions on Twitter

Compare MYNZ with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Diagnostics & Research icon
MYNZ
Mainz Biomed N V
2.98 6.62M 895.50K -26.30M -23.84M -1.64
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
437.91 165.21B 42.88B 6.34B 7.27B 16.53
Diagnostics & Research icon
DHR
Danaher Corp
181.77 130.05B 23.88B 3.90B 5.30B 5.28
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
393.73 31.91B 3.90B 887.87M 798.08M 10.67
Diagnostics & Research icon
A
Agilent Technologies Inc
103.00 29.38B 6.53B 1.26B 1.31B 4.35
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
154.73 27.28B 15.41B 1.37B 2.11B 7.50

Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-14-25 Initiated Maxim Group Buy
Nov-25-24 Downgrade H.C. Wainwright Buy → Neutral
Nov-21-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Jun-21-22 Initiated H.C. Wainwright Buy

Mainz Biomed N V Stock (MYNZ) Latest News

pulisher
Apr 02, 2025

Mainz BioMed's Trial To Bring Critical Early Cancer Detection One Step Closer - Benzinga

Apr 02, 2025
pulisher
Apr 01, 2025

Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Mainz Biomed Reports 2024 Financial Success and Strategic Advances - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.

Apr 01, 2025
pulisher
Apr 01, 2025

Virtu Financial LLC Takes $79,000 Position in Mainz Biomed (NASDAQ:MYNZ) - Defense World

Apr 01, 2025
pulisher
Apr 01, 2025

Mainz Biomed (MYNZ) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Apr 01, 2025
pulisher
Mar 28, 2025

Mainz Biomed begins pivotal colorectal cancer test study By Investing.com - Investing.com Canada

Mar 28, 2025
pulisher
Mar 27, 2025

Mainz Biomed Enrolls First Patient In EAArly DETECT 2 Study To Advance Colorectal Cancer Test - Nasdaq

Mar 27, 2025
pulisher
Mar 27, 2025

Mainz Biomed begins pivotal colorectal cancer test study - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Revolutionary AI-Powered Cancer Test: Mainz Biomed Begins Major Clinical Trial - Stock Titan

Mar 27, 2025
pulisher
Mar 17, 2025

(MYNZ) Proactive Strategies - Stock Traders Daily

Mar 17, 2025
pulisher
Mar 13, 2025

Mainz Biomed secures license for pancreatic cancer test By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Mainz Biomed Licenses MRNA Biomarkers For Non-Invasive Pancreatic Cancer Screening Test - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Mainz Biomed, Liquid Biosciences Partner on Blood-Based Test for Pancreatic Cancer - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Mainz Biomed’s Breakthrough in Pancreatic Cancer Detection - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

Mainz Biomed secures license for pancreatic cancer test - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer - The Manila Times

Mar 13, 2025
pulisher
Mar 13, 2025

Mainz Biomed Signs Exclusive Licensing Agreement with Liquid Biosciences for Novel mRNA Biomarkers in Pancreatic Cancer Detection - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Mainz Biomed and Liquid Biosciences Make Groundbreaking - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood ... - The Bakersfield Californian

Mar 13, 2025
pulisher
Mar 03, 2025

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

Can Mainz Biomed's 82% Detection Rate Technology Revolutionize Colorectal Cancer Prevention? - StockTitan

Mar 03, 2025
pulisher
Feb 24, 2025

(MYNZ) Trading Advice - Stock Traders Daily

Feb 24, 2025
pulisher
Feb 20, 2025

Mainz Biomed Expands into Switzerland with labor team w - GlobeNewswire

Feb 20, 2025
pulisher
Feb 20, 2025

Mainz Biomed Partners with labor team w ag to Launch ColoAlert® Colorectal Cancer Screening Test in Switzerland - Nasdaq

Feb 20, 2025
pulisher
Feb 20, 2025

First DNA-Based Cancer Test Enters Swiss Market: Can Mainz Biomed Transform Screening? - StockTitan

Feb 20, 2025
pulisher
Feb 16, 2025

Mainz Biomed (NASDAQ:MYNZ) Coverage Initiated at Maxim Group - Defense World

Feb 16, 2025
pulisher
Feb 14, 2025

Maxim Group Initiates Coverage of Mainz Biomed N.V. (MYNZ) with Buy Recommendation - Nasdaq

Feb 14, 2025
pulisher
Feb 14, 2025

This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga

Feb 14, 2025
pulisher
Feb 13, 2025

How To Trade (MYNZ) - Stock Traders Daily

Feb 13, 2025
pulisher
Feb 11, 2025

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced - GlobeNewswire

Feb 11, 2025
pulisher
Feb 11, 2025

Mainz Biomed Collaborates with GANZIMMUN Diagnostics to Launch Enhanced ColoAlert Colorectal Cancer Screening Test in Germany - Nasdaq

Feb 11, 2025
pulisher
Feb 11, 2025

Mainz Biomed's Revolutionary DNA Tech Powers New German Cancer ScreeningWhat Sets It Apart - StockTitan

Feb 11, 2025
pulisher
Feb 06, 2025

A stock that deserves closer examination: Mainz Biomed N.V (MYNZ) - US Post News

Feb 06, 2025
pulisher
Feb 04, 2025

The Future of Mainz Biomed N.V: Analyzing MYNZ - The InvestChronicle

Feb 04, 2025
pulisher
Jan 28, 2025

Mainz Biomed regains Nasdaq compliance with equity rule By Investing.com - Investing.com Canada

Jan 28, 2025
pulisher
Jan 27, 2025

Mainz Biomed regains Nasdaq compliance with equity rule - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

Mainz Biomed Regains Nasdaq Listing Compliance - TipRanks

Jan 27, 2025
pulisher
Jan 27, 2025

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements - GlobeNewswire

Jan 27, 2025
pulisher
Jan 27, 2025

Mainz Biomed Achieves Full Nasdaq Compliance, Secures Market Position - StockTitan

Jan 27, 2025
pulisher
Jan 27, 2025

Mainz Biomed Regains Compliance With Nasdaq Listing Rules - Nasdaq

Jan 27, 2025
pulisher
Jan 24, 2025

Mainz Biomed (MYNZ) Stock Price, News & Analysis - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Mainz Biomed (NASDAQ:MYNZ) Shares Down 3.7% – What’s Next? - Defense World

Jan 24, 2025
pulisher
Jan 21, 2025

Mainz Biomed Initiates U.S. Clinical Study to Evaluate - GlobeNewswire

Jan 21, 2025
pulisher
Jan 21, 2025

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on - The Bakersfield Californian

Jan 21, 2025
pulisher
Jan 21, 2025

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - Marketscreener.com

Jan 21, 2025
pulisher
Jan 21, 2025

Mainz Biomed Moves Forward With Pivotal CRC Study After Feasibility Trial - Nasdaq

Jan 21, 2025
pulisher
Jan 14, 2025

Mainz Biomed B.V. Addresses Nasdaq Listing Compliance Issue - TipRanks

Jan 14, 2025
pulisher
Jan 02, 2025

Mainz Biomed (NASDAQ:MYNZ) Stock Price Down 5.3% – Here’s Why - Defense World

Jan 02, 2025
pulisher
Dec 21, 2024

MYNZMainz Biomed N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan

Dec 21, 2024

Mainz Biomed N V Stock (MYNZ) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$133.87
price down icon 3.49%
diagnostics_research DGX
$164.18
price down icon 3.78%
diagnostics_research LH
$225.00
price down icon 3.62%
diagnostics_research WAT
$324.92
price down icon 5.85%
diagnostics_research MTD
$1,022.66
price down icon 6.63%
diagnostics_research IQV
$154.73
price down icon 7.73%
Cap:     |  Volume (24h):